This experiment aims to optimize dosing regimens for tau-targeting immunotherapies in Alzheimer's disease models, with the goal of maximizing neuroprotection while minimizing adverse effects.
Primary Hypothesis: Optimal dosing of anti-tau antibodies will result in significant reduction of neurofibrillary tangles and improved cognitive function in tauopathy mouse models, with a therapeutic window between 10-30 mg/kg administered weekly.
Secondary Hypothesis: Combination therapy with anti-amyloid immunotherapy will show synergistic benefits.
Tau pathology correlates strongly with cognitive decline in Alzheimer's disease. Several anti-tau immunotherapies have entered clinical trials, but dosing optimization remains challenging. Key challenges include:
- Blood-brain barrier penetration efficiency
- Optimal antibody isotype for Fc receptor-mediated clearance
- Timing of intervention relative to disease stage
- Minimizing ARIA (Amyloid-Related Imaging Abnormalities) when combined with anti-amyloid therapy
- Primary: P301S tau transgenic mice (Jackson Labs, strain #008169)
- Age: 3-month-old mice (pre-symptomatic) and 9-month-old mice (symptomatic)
- Groups:
- Control (IgG isotype, n=20)
- Low dose (10 mg/kg, n=20)
- Medium dose (20 mg/kg, n=20)
- High dose (30 mg/kg, n=20)
- Combination (anti-tau + anti-Aβ, n=20)
- Antibodies administered via intraperitoneal injection
- Weekly treatments for 16 weeks
- Behavioral testing at weeks 4, 8, 12, and 16
- Terminal sacrifice at week 16 for histopathology
- Primary: Tau pathology burden (AT8 immunohistochemistry) in hippocampus and cortex
- Secondary:
- Cognitive performance (Morris water maze, novel object recognition)
- CSF tau levels (through longitudinal sampling)
- Neuroinflammation markers (Iba1, CD68, GFAP)
- ARIA assessment (MRI)
¶ Reagents and Equipment
| Item |
Supplier |
Cost (USD) |
| Anti-tau antibody (HJ8.5) |
BioLegend |
$5,000 |
| Anti-Aβ antibody (BAN2401) |
BioSource |
$8,000 |
| AT8 antibody |
Thermo Fisher |
$450 |
| Iba1 antibody |
Wako |
$350 |
| GFAP antibody |
Dako |
$300 |
| Morris water maze apparatus |
Stoelting |
$12,000 |
| Cryostat |
Leica |
$45,000 |
| Stereo injector |
Harvard Apparatus |
$8,000 |
Estimated Total Cost: $80,000
- Mayo Clinic — Dr. Leonard Petrucelli's group (tau biology expertise)
- UC San Diego — Dr. Paul Seidler's group (immunotherapy)
- Washington University — Dr. David Holtzman's group (in vivo models)
- University of Cambridge — Dr. Michel Goedert's group (tau propagation)
- Months 1-2: Animal ordering, colony establishment, antibody production
- Months 3-6: Treatment phase and behavioral testing
- Months 7-8: Tissue processing and immunohistochemistry
- Months 9-10: Data analysis and manuscript preparation
Total Duration: 10 months
- 40-60% reduction in hippocampal tau pathology at optimal dose
- Dose-response curve with clear therapeutic window
- No significant increase in ARIA incidence at optimized dose
- Improved performance in Morris water maze (20-30% improvement in target quadrant time)
- 30-50% reduction in CSF total tau
- Reduced microglial activation in treatment groups
- Weekly monitoring for adverse effects
- Pre-specified stopping rules if >20% mortality
- MRI screening for ARIA before treatment escalation
| Dimension |
Score (1-10) |
Rationale |
| Scientific Value |
9 |
Directly addresses critical gap in tau immunotherapy |
| Feasibility |
8 |
Established mouse models and antibodies available |
| Novelty |
7 |
First systematic dose-optimization study |
| Disease Impact |
9 |
Potential to improve clinical trial outcomes for AD |
| Reach |
8 |
Applicable to all tauopathies, not just AD |
| Cost Efficiency |
7 |
Moderate cost for comprehensive study |
| Time Efficiency |
8 |
10-month timeline is reasonable |
| Evidence Base |
8 |
Strong preclinical data supporting approach |
| Addresses Uncertainty |
9 |
Resolves key dosing questions |
| Translation Potential |
9 |
Direct relevance to clinical development |
Total Score: 82 × weight normalization = 82/120